
Cantel Medical Corp. CMD
Cantel Medical Corp. Financial Ratios 2011-2025 | CMD
Annual Financial Ratios Cantel Medical Corp.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
165.8 | 69.8 | 43.7 | 45.9 | 52.4 | 43.3 | 34.4 | 27.2 | 22.5 | 20.8 |
P/S |
2.2 | 4.2 | 4.6 | 4.3 | 4.7 | 3.7 | 3.0 | 2.5 | 1.8 | 1.3 |
EV/EBITDA |
24.9 | 32.0 | 26.1 | 23.4 | 26.4 | 20.3 | 17.1 | 14.0 | 11.3 | 9.8 |
PEG |
-2.2 | -1.76 | 1.58 | 2.44 | 2.1 | 4.43 | 3.41 | 1.14 | 0.48 | 1608.94 |
P/B |
3.1 | 5.8 | 6.5 | 6.3 | 6.9 | 5.1 | 4.1 | 3.3 | 2.6 | 1.8 |
P/CF |
22.1 | -134.7 | 45.1 | 40.4 | 51.1 | 44.8 | 29.3 | 23.8 | 15.7 | 19.0 |
ROE % |
1.88 | 8.32 | 14.95 | 13.62 | 13.19 | 11.79 | 11.85 | 12.22 | 11.36 | 8.72 |
ROA % |
0.66 | 5.14 | 9.45 | 9.08 | 8.63 | 8.21 | 8.07 | 8.05 | 7.21 | 6.35 |
ROCE % |
2.55 | 9.09 | 14.68 | 16.25 | 16.26 | 15.73 | 15.10 | 14.75 | 13.73 | 11.27 |
DSO |
65.5 | 58.9 | 49.7 | 52.4 | 51.2 | 45.1 | 46.5 | 46.3 | 47.1 | 52.3 |
DIO |
105.7 | 102.8 | 85.8 | 89.4 | 93.9 | 84.4 | 79.2 | 81.9 | 76.8 | 73.5 |
DPO |
26.4 | 29.3 | 27.3 | 24.9 | 27.0 | 19.0 | 25.9 | 20.1 | 20.3 | 24.3 |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Cantel Medical Corp., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Baxter International
BAX
|
$ 18.99 | 0.48 % | $ 9.68 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 200.87 | 0.22 % | $ 57.8 B | ||
|
BioLife Solutions
BLFS
|
$ 24.43 | -1.81 % | $ 1.13 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 4.79 | 2.35 % | $ 96.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Repro Med Systems
KRMD
|
$ 5.75 | -1.88 % | $ 262 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
LeMaitre Vascular
LMAT
|
$ 83.51 | 0.18 % | $ 1.87 B | ||
|
Masimo Corporation
MASI
|
$ 138.1 | -2.25 % | $ 7.36 B | ||
|
ICU Medical
ICUI
|
$ 147.72 | 0.34 % | $ 3.6 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Merit Medical Systems
MMSI
|
$ 86.52 | -0.01 % | $ 5.04 B | ||
|
Alcon
ALC
|
$ 78.74 | -0.03 % | $ 40.4 B | ||
|
iRhythm Technologies
IRTC
|
$ 170.09 | 0.58 % | $ 5.31 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
AtriCure
ATRC
|
$ 42.08 | 1.62 % | $ 1.98 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
electroCore
ECOR
|
$ 4.81 | -0.21 % | $ 26.5 K | ||
|
Harvard Bioscience
HBIO
|
$ 0.76 | 1.78 % | $ 32.2 M | ||
|
InfuSystem Holdings
INFU
|
$ 9.24 | 0.33 % | $ 191 M | ||
|
AngioDynamics
ANGO
|
$ 13.12 | -2.42 % | $ 536 M | ||
|
The Cooper Companies
COO
|
$ 81.82 | -0.36 % | $ 16.3 B | ||
|
Predictive Oncology
POAI
|
$ 5.95 | 0.51 % | $ 32.4 M | ||
|
Glaukos Corporation
GKOS
|
$ 109.57 | 0.31 % | $ 5.31 B | ||
|
Haemonetics Corporation
HAE
|
$ 83.2 | -1.49 % | $ 4.19 B | ||
|
Repligen Corporation
RGEN
|
$ 156.65 | -3.1 % | $ 8.73 M | ||
|
Envista Holdings Corporation
NVST
|
$ 21.79 | -1.58 % | $ 3.75 B | ||
|
OraSure Technologies
OSUR
|
$ 2.52 | -2.14 % | $ 188 M | ||
|
Intuitive Surgical
ISRG
|
$ 541.3 | -1.11 % | $ 192 B | ||
|
Nephros
NEPH
|
$ 5.08 | 2.24 % | $ 52.8 M | ||
|
Microbot Medical
MBOT
|
$ 2.43 | 2.21 % | $ 24.8 M | ||
|
STAAR Surgical Company
STAA
|
$ 24.16 | -2.11 % | $ 1.19 B | ||
|
Milestone Scientific
MLSS
|
$ 0.39 | 9.69 % | $ 31.1 M | ||
|
ResMed
RMD
|
$ 250.7 | -0.67 % | $ 36.6 B | ||
|
Stereotaxis
STXS
|
$ 2.38 | -1.45 % | $ 192 M | ||
|
STERIS plc
STE
|
$ 251.01 | -0.59 % | $ 24.7 B | ||
|
Pro-Dex
PDEX
|
$ 43.83 | 0.6 % | $ 144 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.26 | 3.71 % | $ 685 M | ||
|
Utah Medical Products
UTMD
|
$ 57.99 | 0.5 % | $ 210 M | ||
|
West Pharmaceutical Services
WST
|
$ 266.92 | -2.06 % | $ 19.5 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.59 | -0.13 % | $ 2.36 B | ||
|
Retractable Technologies
RVP
|
$ 0.83 | -0.31 % | $ 24.8 M | ||
|
Teleflex Incorporated
TFX
|
$ 125.81 | -1.13 % | $ 5.89 B |